We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$344M
AUM Growth
+$103M
Cap. Flow
+$45.6M
Cap. Flow %
13.27%
Top 10 Hldgs %
87.9%
Holding
39
New
12
Increased
2
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$38.8M
2
NVO
Novo Nordisk
NVO
+$3.93M
3
INSM icon
Insmed
INSM
+$1.94M
4
VRNA
Verona Pharma
VRNA
+$1.93M
5
OCUL icon
Ocular Therapeutix
OCUL
+$1.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$10.9M
2
ROIV icon
Roivant Sciences
ROIV
+$10.7M
3
ETNB
89bio
ETNB
+$7.19M
4
ARGX icon
argenx
ARGX
+$6.99M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.93M

Sector Composition

Rank Sector Weight
1 Healthcare 73.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPT
26
DELISTED
RAPT Therapeutics
RAPT
$488K 0.14%
+2,455
New +$304K
GPCR icon
27
PUT
Structure Therapeutics
GPCR
$3.44B
$408K 0.12%
+10,000
New +$573K
BMEA icon
28
Biomea Fusion
BMEA
$86.8M
$370K 0.11%
25,452
– –
APGE icon
29
Apogee Therapeutics
APGE
$10.1B
$290K 0.08%
+10,381
New +$208K
GRTS
30
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$194K 0.06%
95,170
– –
TYRA icon
31
Tyra Biosciences
TYRA
$1.91B
$142K 0.04%
10,253
-35,000
-77% -$453K
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$29.5B
– –
-15,971
Closed -$2.83M
ETNB
33
DELISTED
89bio
ETNB
– –
-465,465
Closed -$7.19M
ROIV icon
34
Roivant Sciences
ROIV
$24.1B
– –
-914,023
Closed -$10.7M
SRPT icon
35
Sarepta Therapeutics
SRPT
$1.68B
– –
-57,162
Closed -$6.93M
TMO icon
36
Thermo Fisher Scientific
TMO
$212B
– –
-2,109
Closed -$1.07M
VRTX icon
37
Vertex Pharmaceuticals
VRTX
$119B
– –
-18,314
Closed -$6.37M
CBAY
38
DELISTED
Cymabay Therapeutics
CBAY
– –
-41,261
Closed -$615K
SGEN
39
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-51,175
Closed -$10.9M
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Artia Global Partners held 39 positions worth $344M, up 43% from $241M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Artia Global Partners deployed $45.6M of net new capital in Q4 2023, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Insmed: 74,936 shares worth $2.32M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $6.99M trimmed.

  • Artia Global Partners's largest Q4 2023 buy was Insmed: 74,936 shares worth $2.32M.
  • Artia Global Partners added most to Eli Lilly in Q4 2023, an estimated $38.8M increase.
  • Artia Global Partners's biggest Q4 2023 reduction was argenx, cutting an estimated $6.99M.
  • Artia Global Partners fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $10.9M.
  • Artia Global Partners's ten largest holdings make up 88% of its $344M portfolio in Q4 2023.
  • Artia Global Partners opened 12 new positions and closed 8 in Q4 2023.
  • Artia Global Partners's portfolio value rose 43% quarter-over-quarter to $344M.

Based on Artia Global Partners's 13F filing for Q4 2023, filed 14 Feb 2024.